Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion

SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldin, Laurel, Elders, Ty, Werhane, Leslie, Korwek, Kimberly, Poland, Russell, Guy, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425746/
https://www.ncbi.nlm.nih.gov/pubmed/34508863
http://dx.doi.org/10.1016/j.ijid.2021.09.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425746/
https://www.ncbi.nlm.nih.gov/pubmed/34508863
http://dx.doi.org/10.1016/j.ijid.2021.09.007

Ejemplares similares